J.P. Morgan analyst Chris Schott maintained a Buy rating on Gilead Sciences (GILD – Research Report) today and set a price target of $115.00.

PFE's non-COVID drugs and contributions from new and newly acquired products are likely to have driven top-line growth in the ...

Drugmakers raised the list prices of more than 800 prescription drugs for blood pressure, cancer and other conditions by a ...

Shares of Pfizer Inc. (NYSE:PFE – Get Free Report) have been given a consensus rating of “Moderate Buy” by the sixteen ...

Dividend stocks can be a great way to boost your portfolio's growth potential or provide a form of passive income over the ...

Equities research analysts at Zacks Research upped their Q1 2026 earnings per share estimates for Pfizer in a report released ...

Diabetes and weight management drugs dominated game-day NFL advertising during the regular season, with TV outcomes company ...